iTeos Therapeutics Inc.

Once a key part of its next-generation plans in cancer, Merck & Co . has called a halt to the last remaining Phase III studies of its TIGIT- and LAG-3 targeting immunotherapy assets. The two immu

Iteos has surged through a competitive field to become the poster boy for TIGIT and a couple of readouts coming before the end of the year show that the Belgian-based firm is far from being a single-a

Among the presentations at the European Society for Medical Oncology meeting in Barcelona, Spain will be data for older immune checkpoint inhibitors from Merck & Co., Inc. , AstraZeneca PLC and Br

Fans of the TIGIT mechanism finally have something to cheer about after iTeos Therapeutics Inc. 's belrestotug impressed in a mid-stage trial lung cancer trial when combined with GSK plc 's PD-1 inh